Loading
Aktis Oncology, Inc. Stock: price and insider trades · United States
US·Mcap US$917.2M
Aktis Oncology, Inc.: what insiders have been doing
Every trade that managers of Aktis Oncology, Inc. disclose to SEC (Form 4) is tracked on this page. From 18 October 2025 to 18 October 2026, the disclosure feed for Aktis Oncology, Inc. logged 29 filings by 13 insiders.
No insider bought on the market over the period, while 3 insiders filed 11 sales totalling €2.8M. Biggest ticket of the year: €756k, sold by Czibere Akos and made public on 10 July 2026 (0.079% of market cap).
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 29 filings, this issuer sits above that mark. Our records for Aktis Oncology, Inc. go back to 2026, with no purchases and 11 sales on the open market in total.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
29
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€3M
11 ops. · all time
Who traded when
BuySaleAkos Czibere5 sales
Ken Herrmann3 sales
Shulamit Ron-Bigger3 sales
Analyst consensus: bullish or bearish?
Analysts rate Aktis Oncology, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$35.39.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.49
Analyst consensus
9 analystsStrong buy
US$31.50Target US$35.39(+115%)US$40.00
Income statement
RevenueUS$6.5M
EBITDA-US$72.4M-1114% margin
Net income-US$63.7M-980.9% margin
Valuation
PER (forward)-7.7x
P/Book1.9x
Balance sheet & cash
Market capUS$917.2M
Total debtUS$11.5M
Free Cash Flow-US$73.7M
Debt / Equity2%
Profitability & ownership
% insiders14.1%
% institutions73.2%
Last declaration on 24 September 2026
Declarations29 total
12,500 shares@ US$4.950.0056% mcap3.2% of flowCommon StockSEC:0001193125-26-401014:0
5,099 shares@ US$20.19470.0094% mcap5.2% of flowCommon StockSEC:0001193125-26-401014:1
7,401 shares@ US$21.03070.014% mcap7.9% of flowCommon StockSEC:0001193125-26-401014:2
25,000 shares@ US$22.11100.0% of flowCommonSEC144:0001950047-26-009770
3,506 shares@ US$0.080.0000% mcap0.1% of flowCommon StockSEC:0001193125-26-310991:0
1,350 shares@ US$1.910.0002% mcap1.3% of flowCommon StockSEC:0001193125-26-310991:1
3,506 shares@ US$24.56220.0078% mcap43.1% of flowCommon StockSEC:0001193125-26-310991:2
1,350 shares@ US$24.56220.0030% mcap16.6% of flowCommon StockSEC:0001193125-26-310991:3
4,856 shares@ US$24.56230.011% mcap60.7% of flowCommonSEC144:0001950047-26-007234
3,065 shares@ US$25.20670.0070% mcap38.7% of flowCommon StockSEC:0001193125-26-309115:1
3,065 shares@ US$0.080.0000% mcap0.1% of flowCommon StockSEC:0001193125-26-309115:0
3,065 shares@ US$25.20670.0070% mcap39.3% of flowCommonSEC144:0001950047-26-007199
30,829 shares@ US$27.95210.079% mcap44.1% of flowCommon StockSEC:0001193125-26-300162:2
4,371 shares@ US$28.70780.011% mcap6.4% of flowCommon StockSEC:0001193125-26-300162:3
30,000 shares@ US$27.93790.077% mcap53.4% of flowCommon StockSEC:0001193125-26-300163:2
4,200 shares@ US$28.74760.011% mcap7.7% of flowCommon StockSEC:0001193125-26-300163:3
14,800 shares@ US$27.12730.037% mcap20.5% of flowCommon StockSEC:0001193125-26-300162:1
15,800 shares@ US$27.13170.039% mcap27.3% of flowCommon StockSEC:0001193125-26-300163:1
50,000 shares@ US$4.950.023% mcap12.7% of flowCommon StockSEC:0001193125-26-300162:0
50,000 shares@ US$3.660.017% mcap11.7% of flowCommon StockSEC:0001193125-26-300163:0
50,000 shares@ US$27.75120.13% mcap100.0% of flowCommonSEC144:0001950047-26-006960
50,000 shares@ US$27.7740.13% mcap100.0% of flowCommonSEC144:0001950047-26-006961
1,314,262 sharesCommon StockSEC:0001231919-26-000057:0
1,314,262 sharesCommon StockSEC:0001231919-26-000055:0
597,391 sharesCommon StockSEC:0001473930-26-000005:0
25 of 29 declarations
About Aktis Oncology, Inc.
Aktis Oncology, Inc. is a company focused on developing innovative cancer treatments. It specializes in targeted therapies to improve patient outcomes.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
